← Leaderboards
Liang Xu
Ascenta Therapeutics, Inc.
$5,966,135
Attributed
$10,350,687
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$10,350,687 · 8
By mechanism
R01$9,009,617 · 5
R33$1,010,110 · 1
R21$224,960 · 1
R41$106,000 · 1
Top collaborators
- Yong Zeng9 shared
- Jeffrey Aube7 shared
- Dan Alan Dixon5 shared
- Kristi L Neufeld3 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMalignant NeoplasmsMolecularTumorValidationIn VitroBaseTumor ProgressionCancer CellProteinsResistanceNeoplasm MetastasisCancer TherapyDrug ResistanceDesignMembraneStructureCell LineOverexpressionChemotherapyMouse ModelApoptosisClinical ResearchSmall Molecule
Grant awards (31)
Integrative Functional Profiling of Tumor-Derived Extracellular Vesicles$256,562
R33 · FY2024 · CA
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy$581,650
R01 · FY2023 · CA · contact PI
Integrative Functional Profiling of Tumor-Derived Extracellular Vesicles$64,488
R33 · FY2023 · CA
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy$581,650
R01 · FY2022 · CA · contact PI
Integrative Functional Profiling of Tumor-Derived Extracellular Vesicles$334,554
R33 · FY2022 · CA
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy$669,271
R01 · FY2021 · CA · contact PI
Integrative Functional Profiling of Tumor-Derived Extracellular Vesicles$354,506
R33 · FY2021 · CA
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy$593,521
R01 · FY2020 · CA · contact PI
Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy$593,521
R01 · FY2019 · CA
Molecular cancer therapy targeting HuR-ARE interaction$419,040
R01 · FY2019 · CA · contact PI
Molecular cancer therapy targeting HuR-ARE interaction$432,001
R01 · FY2018 · CA · contact PI
Molecular cancer therapy targeting HuR-ARE interaction$432,001
R01 · FY2017 · CA · contact PI
Small molecules modulating RNA-binding protein Msi1$432,491
R01 · FY2016 · CA · contact PI
Molecular cancer therapy targeting HuR-ARE interaction$432,001
R01 · FY2016 · CA · contact PI
Small molecules modulating RNA-binding protein Msi1$432,491
R01 · FY2015 · CA · contact PI
Molecular cancer therapy targeting HuR-ARE interaction$432,001
R01 · FY2015 · CA · contact PI
Small molecules modulating RNA-binding protein Msi1$432,491
R01 · FY2014 · CA · contact PI
Molecular cancer radiosensitization by targeting Mcl-1$304,003
R01 · FY2010 · CA · contact PI
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectors$253,359
R01 · FY2010 · CA · contact PI
Molecular cancer radiosensitization by targeting Mcl-1$13,091
R01 · FY2010 · CA · contact PI
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectors$5,228
R01 · FY2010 · CA · contact PI
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectors$340,575
R01 · FY2009 · CA · contact PI
Molecular cancer radiosensitization by targeting Mcl-1$313,340
R01 · FY2009 · CA · contact PI
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectors$273,821
R01 · FY2009 · CA · contact PI
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectors$258,587
R01 · FY2009 · CA · contact PI
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectors$258,587
R01 · FY2008 · CA · contact PI
Tumor targeted RNAi by novel nanovectors for molecular therapy of prostate cancer$127,680
R21 · FY2008 · CA · contact PI
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectors$258,587
R01 · FY2007 · CA · contact PI
Tumor targeted RNAi by novel nanovectors for molecular therapy of prostate cancer$97,280
R21 · FY2007 · CA · contact PI
Tumor-targeted silencing of Bcl-2/Bcl-xL by the self-assembled siRNA-nanovectors$266,309
R01 · FY2006 · CA · contact PI
Radiosensitization by modulating inhibitors of apoptosis$106,000
R41 · FY2005 · CA